Proteasome Inhibition by Carfilzomib Induced Apotosis and Autophagy in a T-cell Acute Lymphoblastic Leukemia Cell Line

Document Type : Research article


1 Department of Laboratory Hematology and Blood Bank, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 HSCT Research Center, Department of Laboratory Hematology and Blood Bank, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Department of Medical Lab Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


T-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy which is usually
associated with unfavorable prognosis particularly in patients with refractory/relapsed disease.
Therefore, development of novel therapeutic strategies is highly required for improving the
outcome of these patients. Although there are several studies evaluating the efficacy of proteasome
inhibitors on acute lymphoblastic leukemia of B-cell lineage, the data are still limited regarding
T-cell acute lymphoblastic leukemia. Here, we tried to investigate the effects of the proteasome
inhibition by carfilzomib on the induction of apoptosis and autophagy in Molt4 cells. The effect
of carfilzomib in combination with dexamethasone in Molt4, as a glucocorticoid-resistant T-cell
acute lymphoblastic leukemia cell line, was also assessed. Our data showed that carfilzomib can
induce both apoptosis and autophagy in Molt4 cells. Furthermore, we found that carfilzomib is
a potent inducer of reactive oxygen species production and also induces G2/M phase cell cycle
arrest in Molt4 cells. Concomitant treatment with carfilzomib and dexamethasone demonstrated
that carfilzomib can synergistically enhance the cytotoxic effect of dexamethasone on Molt4
cells. Furthermore, co-treatment of the cells with carfilzomib and dexamethasone increased
the induction of autophagy as compared with each drug alone. In conclusion, our results are
suggestive of the effectiveness of carfilzomib on Molt4 cells as a model of GC-resistant T-cell
acute lymphoblastic leukemia.


Main Subjects

(1) Terwilliger T and Abdul-Hay M. Acute lymphoblastic
leukemia: a comprehensive review and 2017 update.
Blood Cancer J. (2017) 7: e577.
(2) Durinck K, Goossens S, Peirs S, Wallaert A, Van
Loocke W, Matthijssens F, Pieters T, Milani G,
Lammens T, Rondou P and Van Roy N. Novel
biological insights in T-cell acute lymphoblastic
leukemia. Exp. Hematol. (2015) 43: 625-39.
(3) Van Vlierberghe P and Ferrando A. The molecular
basis of T cell acute lymphoblastic leukemia. J. Clin.
Invest. (2012) 122: 3398-406.
(4) Sterz J, Metzler IV, Hahne JC, Lamottke B,
Rademacher J, Heider U, Terpos E and Sezer O. The
potential of proteasome inhibitors in cancer therapy.
Expert. Opin. Inv. Drug (2008) 17: 879-95.
(5) Du XL and Chen Q. Recent advancements of
bortezomib in acute lymphocytic leukemia treatment.
Acta Haematol. (2013) 129: 207-14.
(6) Niewerth D, Dingjan I, Cloos J, Jansen G and
Kaspers G. Proteasome inhibitors in acute leukemia.
Expert Rev. Anticancer Ther. (2013) 13: 327-37.
(7) Junk S, Cario G, Wittner N, Stanulla M, Scherer
R, Schlegelberger B, Schrappe M, von Neuhoff N
and Lauten M. Bortezomib treatment can overcome
glucocorticoid resistance in childhood B-cell
precursor acute lymphoblastic leukemia cell lines.
Klin. Padiatr. (2015) 227: 123-30.
(8) Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso
R, Algeri M, Coletti V, Gurnari C, Romano M, Cefalo
MG and Girardi K. The combination of bortezomib
with chemotherapy to treat relapsed/refractory
acute lymphoblastic leukaemia of childhood. Br. J.
Haematol. (2017) 176: 629-36.
(9) Wartman LD, Fiala MA, Fletcher T, Hawkins ER,
Cashen A, DiPersio JF, Jacoby MA, StockerlGoldstein KE, Pusic I, Uy GL and Westervelt P. A
phase I study of carfilzomib for relapsed or refractory
acute myeloid and acute lymphoblastic leukemia.
Leuk. Lymphoma (2016) 57: 728-30.
(10) Korolchuk VI, Menzies FM and Rubinsztein DC.
Mechanisms of cross‐talk between the ubiquitin‐
proteasome and autophagy‐lysosome systems.
FEBS Lett. (2010) 584: 1393-8.
(11) Fan T, Huang Z, Chen L, Wang W, Zhang B, Xu
Y, Pan S, Mao Z, Hu H and Geng Q. Associations
between autophagy, the ubiquitin-proteasome
system and endoplasmic reticulum stress in
hypoxia-deoxygenation or ischemia-reperfusion.
Eur. J. Pharmacol. (2016) 791: 157-67.
(12) Crawford LJ, Walker B and Irvine AE. Proteasome
inhibitors in cancer therapy. J. Cell Commun.
Signal. (2011) 5: 101-10.
(13) Chou TC. Drug combination studies and their
synergy quantification using the Chou-Talalay
method. Cancer Res. (2010) 70: 440-6.
(14) Ri M. Endoplasmic-reticulum stress pathwayassociated mechanisms of action of proteasome
inhibitors in multiple myeloma. Int. J. Hematol.
(2016) 104: 273-80.
(15) Takahashi K, Inukai T, Imamura T, Yano M,
Tomoyasu C, Lucas DM, Nemoto A, Sato H,
Huang M, Abe M and Kagami K. Anti-leukemic
activity of bortezomib and carfilzomib on B-cell
precursor ALL cell lines. PLoS One (2017) 12:
(16) Bonapace L, Bornhauser BC, Schmitz M, Cario
G, Ziegler U, Niggli FK, Schäfer BW, Schrappe
M, Stanulla M and Bourquin JP. Induction of 
Hosseini MS et al. / IJPR (2019), 18 (Special Issue): 132-145
autophagy-dependent necroptosis is required for
childhood acute lymphoblastic leukemia cells to
overcome glucocorticoid resistance. J. Clin. Invest.
(2010) 120: 1310-23.
(17) Messinger YH, Gaynon PS, Sposto R, van der
Giessen J, Eckroth E, Malvar J, Bostrom BC and
Therapeutic Advances in Childhood Leukemia
and Lymphoma (TACL) Consortium. Bortezomib
with chemotherapy is highly active in advanced
B-precursor acute lymphoblastic leukemia:
therapeutic advances in childhood leukemia and
lymphoma (TACL) study. Blood (2012) 120: 285-
(18) Obeng EA, Carlson LM, Gutman DM, Harrington
WJ, Lee KP and Boise LH. Proteasome inhibitors
induce a terminal unfolded protein response in
multiple myeloma cells. Blood (2006) 107: 4907-16.
(19) Kawaguchi T, Miyazawa K, Moriya S, Ohtomo T,
Che XF, Naito M, Itoh M and Tomoda A. Combined
treatment with bortezomib plus bafilomycin
A1 enhances the cytocidal effect and induces
endoplasmic reticulum stress in U266 myeloma
cells: crosstalk among proteasome, autophagylysosome and ER stress. Int. J. Oncol. (2011) 38:
(20) Koga T, Suico MA, Shimasaki S, Watanabe E, Kai
Y, Koyama K, Omachi K, Morino-Koga S, Sato T,
Shuto T and Mori K. Endoplasmic reticulum (ER)
stress induces sirtuin 1 (SIRT1) expression via the
PI3K-Akt-GSK3β signaling pathway and promotes
hepatocellular injury. J. Biol. Chem. (2015) 290:
(21) Ghosh HS, Reizis B and Robbins PD. SIRT1
associates with eIF2-alpha and regulates the
cellular stress response. Sci. Rep. (2011) 1: 150.
(22) Ou X, Lee MR, Huang X, Messina‐Graham S
and Broxmeyer HE. SIRT1 positively regulates
autophagy and mitochondria function in embryonic
stem cells under oxidative stress. Stem Cells (2014)
32: 1183-94.
(23) Liu JW, Chandra D, Rudd MD, Butler AP, Pallotta
V, Brown D, Coffer PJ and Tang DG. Induction
of prosurvival molecules by apoptotic stimuli:
involvement of FOXO3a and ROS. Oncogene
(2005) 24: 2020-31.
(24) Zhou J, Liao W, Yang J, Ma K, Li X, Wang Y,
Wang D, Wang L, Zhang Y, Yin Y and Zhao Y.
FOXO3 induces FOXO1-dependent autophagy by
activating the AKT1 signaling pathway. Autophagy
(2012) 8: 1712-23.
(25) Rastogi N and Mishra DP. Therapeutic targeting of
cancer cell cycle using proteasome inhibitors. Cell
Div. (2012) 7: 26.
(26) Laane E, Tamm KP, Buentke E, Ito K, Khahariza P,
Oscarsson J, Corcoran M, Björklund AC, Hultenby
K, Lundin J and Heyman M. Cell death induced by
dexamethasone in lymphoid leukemia is mediated
through initiation of autophagy. Cell Death Differ.
(2009) 16: 1018.